Short answer
Neurogene Inc. (NGNE) filed its Q3 2025 10-Q quarterly report on Nov 13, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $0 with net income of −$21M.
Q3 2025 key financials · XBRL
- Revenue
- $0
- Net income
- −$21M
- −3.6% YoY · +4.8% QoQ
- EPS (diluted)
- −$0.99
- +17.5% YoY · +4.8% QoQ
Source: XBRL data from the Neurogene Inc. (NGNE) Q3 2025 10-Q on SEC EDGAR. USD.
Neurogene Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No product revenue; licensing revenue from legacy Neoleukin asset agreements
- Net loss $65.6M for nine months ended September 30, 2025 vs $55.6M YoY
- Cash, equivalents and short-term investments $265.4M at September 30, 2025
- Phase 1/2 NGN-401 pediatric cohort: 35 developmental milestones gained across core domains
- Embolden enrollment expected to complete in three to six months; expenses and capital requirements expected to increase substantially
Risk Factors
- NGN-101 program discontinuation risk triggered by FDA’s November 2024 RMAT designation denial
- Regulatory pathway risk from FDA denial, eliminating the streamlined registration route needed for NGN-101 investment
- Clinical development risk as Embolden registrational trial of NGN-401 remains unproven
- Competitive risk from safer, more effective, less invasive, or lower-cost Rett syndrome treatments
- Liquidity risk with $327.9 million cumulative net losses and funding projected through first quarter of 2028
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Neurogene Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.